Core Viewpoint - Rosen Law Firm is reminding former stockholders of Smartsheet Inc. about a class action lawsuit related to the January 2025 sale of Smartsheet to a consortium including Blackstone, Vista Equity Partners, and Platinum Falcon, with a lead plaintiff deadline set for February 24, 2026 [1]. Group 1: Class Action Details - Former Smartsheet stockholders may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by February 24, 2026 [3]. - Investors are encouraged to select qualified legal counsel with a successful track record in securities class actions [4]. Group 2: Allegations Against Smartsheet - The complaint alleges that Smartsheet's solicitation of stockholder approval for the Buyout involved a false and misleading Schedule 14A Proxy statement, which mischaracterized the company's financial performance [5]. - Defendants are accused of deliberately presenting Smartsheet's quarterly earnings negatively and emphasizing a fabricated financial metric to solicit approval for the Buyout [5].

NEW YORK, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Kirby McInerney LLP reminds Klarna Group plc (“Klarna” or the “Company”) (NYSE: KLAR) investors of the February 20, 2026 deadline to seek the role of lead plaintiff in a pending federal securities class action. If you purchased or otherwise acquired Klarna securities, have information, or would like to learn more, please contact Lauren Molinaro of Kirby McInerney LLP by email at investigations@kmllp.com, or fill out the form below, to discuss your rights or intere ...

What Is This Lawsuit About? The lawsuit alleges that agilon made false and/or misleading statements and/or failed to disclose that: (1) agilon recklessly issued guidance for 2025 that the Company knew or should have known was not going to be achieved, given material industry headwinds of which the Company was aware; and (2) materially overstated the immediate positive financial impact from "strategic actions†taken by agilon to reduce risk. On August 4, 2025, agilon issued a press release entitled "agilon He ...

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP reminds Freeport-McMoran Inc. ("Freeport†or the "Company†) (NYSE:FCX) investors of the January 12, 2026 deadline to seek lead plaintiff appointment in the class action filed on behalf of investors who acquired Freeport securities between February 15, 2022 through September 24, 2025 ("the Class Period†). Follow the link below for more information: [LEARN MORE ABOUT THE LEAD PLAINTIFF PROCESS] What Is The Lawsuit About? Kirby McInerney LLP is ...

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Skye Bioscience, Inc. securities during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1]. Group 1: Class Action Details - The Class Period for the Skye Bioscience securities is from November 4, 2024, to October 3, 2025 [1]. - Investors who purchased Skye securities during this period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by January 16, 2026 [2]. Group 2: Legal Representation - Investors are encouraged to select qualified legal counsel with a proven track record in securities class actions [3]. - Rosen Law Firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company and has been ranked highly for its success in this area [3]. - The firm has recovered hundreds of millions of dollars for investors, with over $438 million secured in 2019 alone [3]. Group 3: Case Allegations - The lawsuit alleges that Skye's defendants made materially false and misleading statements regarding the effectiveness of nimacimab, overstating its clinical, regulatory, and commercial prospects [4]. - The claims suggest that when the true details about nimacimab were revealed, investors suffered damages due to the misleading information provided by the defendants [4].

NEW YORK, Jan. 09, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Primo Water Corporation (NYSE: PRMW) between June 17, 2024 and November 8, 2024, both dates inclusive, and/or (ii) purchasers of common stock of Primo Brands Corporation (NYSE: PRMB) between November 11, 2024 and November 6, 2025 (the “Class Period”), of the important January 12, 2026 lead plaintiff deadline. SO WHAT: If you purchased Primo Brands securities during the C ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Varonis To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Varonis between February 4, 2025 and October 28, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information]New York, New York--(Newsfile Corp. - January 9, 20 ...

Core Viewpoint - The article highlights a pending securities class action lawsuit against Telix Pharmaceuticals Ltd. due to alleged misstatements regarding the company's therapeutic candidates and regulatory compliance, which resulted in significant investor losses [1][2][3]. Regulatory Issues - The lawsuit follows regulatory setbacks, including an SEC subpoena and a Complete Response Letter (CRL) from the FDA, leading to a 21% decline in stock price [2][6]. - The SEC is questioning the development disclosures, while the FDA rejected a Biologics License Application (BLA) due to deficiencies in Chemistry, Manufacturing, and Controls (CMC) at third-party manufacturers [3][6]. Allegations of Misrepresentation - The complaint alleges that Telix and its executives overstated the developmental progress of therapeutic candidates and misrepresented the reliability of their supply chain and manufacturing partners [2][3]. - Documented failures in regulatory compliance were allegedly concealed, contradicting claims of "great progress" and "global manufacturing capability" [3][4]. Investor Impact - Investors who purchased Telix ADSs during the Class Period (February 21, 2025 – August 28, 2025) reportedly suffered substantial losses due to undisclosed flaws in supply chain and therapeutic progress [5][6]. - The cumulative effect of the regulatory disclosures led to a sharp decline in Telix ADSs, with a notable 21% drop following the final regulatory news [6]. Next Steps for Investors - Hagens Berman encourages affected Telix investors to contact the firm to discuss their rights and potential recovery options [4][5].

NEW YORK, Jan. 08, 2026 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of agilon health, inc. (NYSE: AGL). Shareholders who purchased shares of AGL during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/agilon-health-inc-loss-submission-form/?id=182869&from=3  CLASS PERIOD: February 2 ...

Faruqi & Faruqi, LLP also encourages anyone with information regarding Ardent's conduct to contact the firm, including whistleblowers, former employees, shareholders and others. The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel ...